Try our Advanced Search for more refined results

Hedge Fund Manager Loses IPR Bids Against Acorda

By Erin Coe (August 24, 2015, 5:57 PM EDT) -- Dealing a setback to an organization with close ties to hedge fund manager Kyle Bass, the Patent Trial and Appeal Board on Monday declined to institute two inter partes reviews of patents covering Acorda Therapeutics Inc.'s multiple sclerosis drug Ampyra....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Law Firms

Companies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!